On February 25, 2020 AIVITA Biomedical, Inc., a biotechnology company (the "Company") specializing in innovative stem cell applications, reported the first closing of its $25 million Series B-2 preferred stock investment round (Press release, AIVITA Biomedical, FEB 25, 2020, View Source [SID1234554716]). The first closing of $12.5 million was led by Matthew Katz, an entrepreneur and investor who has been appointed to AIVITA’s board of directors. The financing round also includes other healthcare-focused venture capital firms.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Matthew Katz is founder and CEO of Verifi, Inc., a customized software solution that systematically identifies payment risk. He is also the head of Zoo Station, his family office focused on investing in early stage startups. He has successfully founded and partnered several businesses and consulting firms and is a welcome addition to AIVITA’s board of directors.

"We are excited to welcome Matthew to our board of directors," said Dr. Hans S. Keirstead, Chairman and CEO of AIVITA. "Matt brings deep experience in corporate development, operations and partnership strategy to AIVITA at a time when our programs are expanding and maturing."